Topics:
Rheumatology • Rheumatoid Arthritis
What is your approach to discussing risk of adverse cardiovascular events in patients with RA whom you are considering starting a JAK inhibitor?
Data is mixed based on the results of ORAL surveillance, STAR-RA and nationwide cohort studies.
Answer from: at Academic Institution
I would refer to the recommendations in the January 28, 2022, position statement by the American College of Rheumatology. This statement emphasizes the importance of shared decision making between the rheumatologist and the patient. There are many options available to treat RA that do not have a sim...
Sign in or Register to read more
Answer from: at Academic Institution
Above all, do no harm. The question is how harmful was TOFA in ORAL? Given demonstrated efficacy what is the number needed to harm and how do risk factors influence this? ASCVD in RA is a moving target and has remarkably declined in the last 15 years probably due to a variety of factors. Where JAK i...